LOGIN  |  REGISTER
Chimerix
Compass Therapeutics

Stryker to participate in the 6th Annual Evercore ISI HealthCONx Conference

October 30, 2023 | Last Trade: US$346.50 0.00 0.00

Kalamazoo, Michigan, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023 at the Kimpton EPIC Hotel in Miami, Florida.

Glenn Boehnlein, Vice President, Chief Financial Officer and Jason Beach, Vice President, Investor Relations will represent the Company in a presentation scheduled for 1:20 p.m. Eastern Time.

A simultaneous webcast and replay of the Company's presentation will be available on Stryker's website at www.stryker.com.  The webcast will be archived on the Investor Relations page of this site.

About Stryker

Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com.

Contacts

For investor inquiries please contact:
Jason Beach, Vice President, Investor Relations at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it. 

For media inquiries please contact:
Yin Becker, Vice President, Chief Corporate Affairs Officer at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page